CN107252110A - 一种增强人体免疫力和抗抑郁保健食品的制备方法 - Google Patents
一种增强人体免疫力和抗抑郁保健食品的制备方法 Download PDFInfo
- Publication number
- CN107252110A CN107252110A CN201710306375.4A CN201710306375A CN107252110A CN 107252110 A CN107252110 A CN 107252110A CN 201710306375 A CN201710306375 A CN 201710306375A CN 107252110 A CN107252110 A CN 107252110A
- Authority
- CN
- China
- Prior art keywords
- parts
- gained
- pseudo
- ginseng
- wilsonii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000036039 immunity Effects 0.000 title claims abstract description 21
- 235000013402 health food Nutrition 0.000 title claims abstract description 14
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 40
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 40
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 37
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 37
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 34
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000706 filtrate Substances 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 19
- 239000006071 cream Substances 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 14
- 239000011122 softwood Substances 0.000 claims abstract description 14
- 230000006837 decompression Effects 0.000 claims abstract description 10
- 238000001914 filtration Methods 0.000 claims abstract description 10
- 238000004806 packaging method and process Methods 0.000 claims abstract description 10
- 235000020985 whole grains Nutrition 0.000 claims abstract description 10
- 239000000080 wetting agent Substances 0.000 claims abstract description 8
- 238000007873 sieving Methods 0.000 claims description 15
- 238000005469 granulation Methods 0.000 claims description 9
- 230000003179 granulation Effects 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 239000003292 glue Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 abstract description 12
- 238000012360 testing method Methods 0.000 description 25
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000012048 forced swim test Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000033065 inborn errors of immunity Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 244000000231 Sesamum indicum Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- -1 flavouring Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000009891 weiqi Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241001489091 Ganoderma sinense Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种增强人体免疫力和抗抑郁保健食品的制备方法,解决现有技术制备方法复杂及不规范的问题。本发明包括以下步骤:首先按重量份数准备原料,原料及其重量配比为:灵芝2~10份、刺五加6~18份、三七4~12份、栀子1~6份;之后将刺五加、栀子加水煎煮,煎液滤过合并,滤液减压浓缩得到清膏备用;再之后将灵芝、三七粉碎过筛,得细粉备用;然后将所得清膏干燥得干浸膏;再然后将所得干浸膏粉碎过筛,得干浸膏粉;再然后将所得细粉与所得干浸膏粉混合均匀,加入适量85%乙醇为湿润剂制软材;最后将步骤6所得软材过筛制粒,干燥,整粒,装胶囊,包装,即得胶囊剂。本发明规范且操作简单、安全有效。
Description
技术领域
本发明涉保健食品领域,尤其涉及一种增强人体免疫力和抗抑郁保健食品的制备方法。
背景技术
人体的免疫功能是一道防线,护卫着人体健康;又是一种祛病能力,在人患病之后可促进康复,这就成为人体强身抗病的根本所在。然而,在日常生活中,有许多因素使人体免疫力下降或出现免疫紊乱。比如,膳食不合理,蛋白质、维生素、微量元素摄入不足;生活不规律,睡眠不足;缺少运动锻炼,对环境的适应能力较差;精神紧张,过度劳累;使用激素、抗生素等药物的不良反应,抑制了免疫力;患急性病时暂时降低了免疫力,患慢性病时则长期处于免疫力低下状态等等。若长时间免疫力低下,人体就会出现健康和疾病的中间状态-亚健康状态。而亚健康状态是不断变化发展的,如不能及时得到改善,很有可能向疾病状态转化。所以,提高人体自身免疫功能,是远离亚健康,走向健康的根本方法。
大量的研究已证实精神状态和免疫***之间存在相互作用,即精神活动能调节免疫功能,而免疫***的紊乱不仅能导致机体疾病,也与心理精神、行为、性格和衰老的变化有关。人体的免疫力低下与抑郁症息息相关。抑郁症能导致人体免疫力下降,免疫力下降又进一步加重抑郁症症状。然而目前安全、有效、适于长期服用的增强人体免疫力又能抗抑郁的药物仍然缺乏。
发明内容
本发明要解决的技术问题是:提供一种增强人体免疫力和抗抑郁保健食品的制备方法,本制备方法操作简单、安全有效,按照该方法制备的保健食品能有效提高机体免疫力,抗抑郁,安全有效。
为实现上述目的,本发明采用的技术方案如下:
一种增强人体免疫力和抗抑郁保健食品的制备方法,包括如下步骤:
步骤1、按重量份数准备原料,所述原料及其重量配比为:灵芝2~10份、刺五加6~18份、三七4~12份、栀子1~6份;
步骤2、将刺五加、栀子加水煎煮,煎液滤过,合并滤液,滤液减压浓缩得到清膏,备用;
步骤3、将灵芝、三七粉碎,过筛,得细粉,备用;
步骤4、将步骤2所得清膏干燥得干浸膏;
步骤5、将步骤4所得干浸膏粉碎过筛,得干浸膏粉;
步骤6、将步骤3所得细粉与步骤5所得干浸膏粉混合均匀,加入适量85%乙醇为湿润剂制软材;
步骤7、将步骤6所得软材过筛制粒,得湿颗粒,湿颗粒干燥,整粒,装胶囊,包装,即得胶囊剂。
所述步骤1中,所述原料及其重量配比为:灵芝3~8份、刺五加7~15份、三七5~10份、栀子2~5份。
所述步骤1中,所述原料及其重量配比为:灵芝4份、刺五加12份、三七 6份、栀子2份。
本发明中所提到的灵芝为为多孔菌科真菌赤芝Ganoderma lucidum(Leyss.exFr.)Karst.或紫芝Ganoderma sinense Zhao,Xuet Zhang的干燥子实体。全年采收,除去杂质,剪除附有朽木、泥沙或培养基质的下端菌柄,阴干或在 烘干,即《中国药典》(2015年版,一部)收载的灵芝。
本发明中所提到的刺五加为五加科植物刺五加Acanthopanax seuticosus(Rupr.et Maxim.)Harms的干燥根和根垄或莲。春、秋二季采收,洗净,干燥,即《中国药典》(2015年版,一部)收载的刺五加。
本发明中所提到的三七为五加科植物三七Parmx notoginseng(Burk.)F. H.Chen的干燥根和根茎。秋季花开前采挖,洗净,分开主根、支根及根茎,干燥。支根习称“筋条”,根茎习称“剪口”,即《中国药典》(2015年版,一部) 收载的三七。
本发明中所提到的栀子为为菌草科植物扼子Ganiema Ellis的干燥成熟果实。月果实成熟呈红黄色时采收,除去果梗和杂质,蒸至上气或置沸水中略烫,取出,干燥,即《中国药典》(2015年版,一部)收载的栀子。
本发明所提到的药学上可接受的辅料,包括填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质等。填充剂包括:淀粉、预胶化淀粉、乳糖、甘露醇、甲壳素、微晶纤维素、蔗糖等;崩解剂包括:淀粉、预胶化淀粉、微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙纤维素、交联羧甲基纤维素钠等;润滑剂包括:硬脂酸镁、十二烷基硫酸钠、滑石粉、二氧化硅等;助悬剂包括:聚乙烯吡咯烷酮、微晶纤维素、蔗糖、琼脂、羟丙基甲基纤维素等;粘合剂包括:淀粉浆、聚乙烯吡咯烷酮、羟丙基甲基纤维素等;甜味剂包括:糖精钠、阿斯帕坦、蔗糖、甜蜜素、甘草次酸等;矫味剂包括:甜味剂及各种香精;防腐剂包括:尼泊金类、苯甲酸、苯甲酸钠、山梨酸及其盐类、苯扎溴铵、醋酸氯乙定、桉叶油等;基质包括:PEG6000, PEG4000,虫蜡等。
灵芝味甘,性平,归心、肺、肝、肾经,具有补气安神,止咳平喘的作用,用于心神不宁,失眠心悸,肺虚咳喘,虚劳短气,不思饮食。
刺五加味辛、微苦,温,归脾、肾、心经,具有益气健脾,补肾安神的作用,用于脾肺气虚,体虚乏力,食欲不振,肺肾两虚,久咳虚喘,肾虚腰膝酸痛,心脾不足,失眠多梦。
三七味甘、微苦,性温,归肝、胃经。具有散瘀止血,消肿定痛的作用,用于咯血,吐血,鯉血,便血,崩漏,外伤出血,胸腹刺痛,跌扑肿痛。
栀子味苦,性寒,归心、肺、三焦经;具有泻火除烦,清热利湿,凉血解毒的作用,用于热病心烦,湿热黄疸,淋证涩痛”血热吐衄,目赤肿痛,火毒疮疡;外治扭挫伤痛。
与现有技术相比,本发明具有以下有益效果:
(1)本发明选用灵芝、刺五加、三七、栀子作为原料药,通过科学组方、按一定的重量配比组成。经动物试验证明,具有增强免疫、抗抑郁的作用,本发明工艺简单,操作简便,原料来源价廉易得,最后所得成品率高,安全有效。
(2)本发明用药精妙,配伍得当,诸药合药,能有效增强免疫和抗抑郁。本发明原料中,灵芝归心、肺、肝、肾经,功能重在补气安神;刺五加归脾、肾、心经,益气健脾,补肾安神;三七归肝、胃经,散瘀止血,消肿定痛;栀子归心、肺、三焦经,泻火除烦。本方以灵芝为君药,取其补气安神之功效,以刺五加为臣药,共奏益气、安神的功效,佐以三七、栀子,泻火除烦、散瘀定痛。全方配方相辅相成,治疗卫气失常所致的卫气虚损、肝郁化滞,从而起到增强免疫力和抗抑郁的作用。
(3)本发明的原料药均为常用的传统中药,易于获得道地药材,原料来源稳定,质量易于控制。
(5)本发明中的灵芝和三七未经提取,直接以全粉入药,最大限度保留了有效成分,减少了用药剂量,同时以粉末入药,减少了辅料的用量。本发明采用科学、合理的制备方法,制备出安全有效的制剂,使得调节机体免疫力的效果更加稳定、可控。
(6)本发明采用了口服制剂,方便生产、储存、运输、携带和服用。
具体实施方式
下面结合实施例对本发明作进一步说明,本发明的方式包括但不仅限于以下实施例。
一种增强人体免疫力和抗抑郁保健食品的制备方法,包括如下步骤:
步骤1、按重量份数准备原料,所述原料及其重量配比为:灵芝2~10份、刺五加6~18份、三七4~12份、栀子1~6份;
步骤2、将刺五加、栀子加水煎煮,煎液滤过,合并滤液,滤液减压浓缩得到清膏,备用;
步骤3、将灵芝、三七粉碎,过筛,得细粉,备用;
步骤4、将步骤2所得清膏干燥得干浸膏;
步骤5、将步骤4所得干浸膏粉碎过筛,得干浸膏粉;
步骤6、将步骤3所得细粉与步骤5所得干浸膏粉混合均匀,加入适量85%乙醇为湿润剂制软材;
步骤7、将步骤6所得软材过筛制粒,得湿颗粒,湿颗粒干燥,整粒,装胶囊,包装,即得胶囊剂。
所述步骤1中,所述原料及其重量配比为:灵芝3~8份、刺五加7~15份、三七5~10份、栀子2~5份。
所述步骤1中,所述原料及其重量配比为:灵芝4份、刺五加12份、三七 6份、栀子2份。
本发明在制备过程中,所述保健食品是以灵芝、刺五加、三七、栀子为原料药,加入药学上可接受的辅料按照常规方法制备而成的制剂;所述制剂由刺五加、栀子用常规方法提取制备成提取物,灵芝、三七制备成细粉制成;所述提取物为水煎物,所述制剂为口服制剂,所述口服制剂可以制成颗粒剂、片剂或胶囊剂中的任意一种。
为了使本技术领域技术人员更好地理解本发明的精髓,特提供以下实施实例加以说明。
实施例1
1.灵芝粉碎工艺考察
方法:称取灵芝净药材3份,各50g,于60℃低温干燥后,粉碎成细粉,过100目筛,称量,计算出粉率,结果见表1。
表1药材粉碎工艺考察结果
试验结果表明,灵芝粉碎的平均出粉率为96.28%。
2.三七粉碎工艺考察
方法:称取三七净药材3份,各50g,于60℃低温干燥后,粉碎成细粉,过100目筛,称量,计算出粉率,结果见表1。
表1药材粉碎工艺考察结果
试验结果表明,灵芝粉碎的平均出粉率为95.61%。
实施例2
组成:灵芝40g、刺五加120g、三七60g、栀子20g、硬脂酸镁3g。
制备方法:按重量份数称取原料;将刺五加、栀子加水煎煮,煎液滤过,合并滤液,滤液减压浓缩得到清膏,干燥,得干浸膏;将灵芝、三七粉碎,过筛,得细粉,与干浸膏混合均匀,加入适量85%乙醇为湿润剂制软材,过筛制粒,得湿颗粒,干燥,加入硬脂酸镁,整粒,装胶囊,包装,即得胶囊剂。
实施例3
组成:灵芝10g、刺五加40g、三七20g、栀子20g、微晶纤维素10g、硬脂酸镁2g。
制备方法:按重量份数称取原料;将刺五加、栀子加水煎煮,煎液滤过,合并滤液,滤液减压浓缩得到清膏,干燥,得干浸膏;将灵芝、三七粉碎,过筛,得细粉,与向晶纤维素、干浸膏混合均匀,加入适量85%乙醇为湿润剂制软材,过筛制粒,得湿颗粒,干燥,加入硬脂酸镁,整粒,压片,包装,即得片剂。
实施例4
组成:灵芝50g、刺五加100g、三七100g、栀子80g、硬脂酸镁5g。
制备方法:按重量份数称取原料;将刺五加、栀子加水煎煮,煎液滤过,合并滤液,滤液减压浓缩得到清膏,干燥,得干浸膏;将灵芝、三七粉碎,过筛,得细粉,与干浸膏混合均匀,加入适量85%乙醇为湿润剂制软材,过筛制粒,得湿颗粒,干燥,加入硬脂酸镁,整粒,装胶囊,包装,即得胶囊剂。
实施例5
组成:灵芝60g、刺五加120g、三七150g、栀子10g、微晶纤维素15g、硬脂酸镁3g。
制备方法:按重量份数称取原料;将刺五加、栀子加水煎煮,煎液滤过,合并滤液,滤液减压浓缩得到清膏,干燥,得干浸膏;将灵芝、三七粉碎,过筛,得细粉,与向晶纤维素、干浸膏混合均匀,加入适量85%乙醇为湿润剂制软材,过筛制粒,得湿颗粒,干燥,加入硬脂酸镁,整粒,压片,包装,即得片剂。
实施例6
组成:灵芝40g、刺五加50g、三七70g、栀子30g、硬脂酸镁4g。
制备方法:按重量份数称取原料;将刺五加、栀子加水煎煮,煎液滤过,合并滤液,滤液减压浓缩得到清膏,干燥,得干浸膏;将灵芝、三七粉碎,过筛,得细粉,与干浸膏混合均匀,加入加入适量85%乙醇为湿润剂制软材,过筛制粒,得湿颗粒,干燥,加入硬脂酸镁,整粒,装胶囊,包装,即得胶囊剂。
实施例7
组成:灵芝30g、刺五加80g、三七40g、栀子60g、硬脂酸镁2g。
制备方法:按重量份数称取原料;将刺五加、栀子加水煎煮,煎液滤过,合并滤液,滤液减压浓缩得到清膏,干燥,得干浸膏;将灵芝、三七粉碎,过筛,得细粉,与干浸膏混合均匀,加入加入适量85%乙醇为湿润剂制软材,过筛制粒,得湿颗粒,干燥,加入硬脂酸镁,整粒,装胶囊,包装,即得胶囊剂。
实施例8
增强免疫力试验
(一)受试药
本发明制剂1:按实施例2制备得胶囊剂,加水制成混悬液。
本发明制剂2:按实施例2制备得片剂,加水制成混悬液。
阴性对照:蒸馏水。
(二)试验动物:雌性ICR小鼠,体重18-22g,由四川省医学科学院实验动物研究所提供。
(三)试验数据采用SPSS 10.0forWindows软件包处理。
(四)试验方法及结果
按照《保健食品检验与评价技术规范》(2003年版)操作。
1、对小鼠细胞免疫功能的影响
1.1对小鼠迟发型***反应(DTH)的影响
1.1.1试验方法:迟发型***反应(DTH)(耳肿胀法)
按照《保健食品检验与评价技术规范》(2003年版)操作。灌胃30天后,给小鼠腹部皮肤脱毛,约3cm×3cm,用DNFB溶液50μl均匀涂抹致敏。5天后,用DNFB溶液10μl涂抹于小鼠右耳(两面)进行攻击。攻击后24小时处死小鼠,剪下左右耳壳,用打孔器取下直径8mm的耳片,称重。
1.1.2试验结果下表。
表1对小鼠迟发型***反应(DTH)的影响
由表1可见,连续灌胃30天后,本发明制剂中、高剂量组动物的耳朵肿胀度与阴性对照组相比较均有显著性差异(P<0.05)。
1.2对ConA诱导的小鼠淋巴细胞转化试验的影响
1.2.1试验方法:ConA诱导的小鼠淋巴细胞转化试验(MTT法)
无菌取脾,置于盛有适量无菌Hank's液的平皿中,制成细胞悬液,经200 目筛网过滤。用Hank's液洗2次,每次离心l0min(1000r/min)。然后将细胞悬浮于1mL完全培养液中,计数活细胞数,用RPMI1640培养液调整细胞浓度为3*106个/mL.。再将细胞悬液分两孔加入24孔培养板中,每孔1mL,在其中一孔加入 75uL ConA液(相当于7.5uL/mL),另一孔作为对照,置5%CO2,37℃二氧化碳孵箱中培养72h。培养结束前4h轻轻吸去上清液0.7mL,加入0.7mL不含小牛血清的RPMI1640培养液,同时加入MTT(5mg/mL)50uL/孔,继续培养4h。培养结束后,每孔加入1mL酸性异丙醇,吹打混匀,使紫色结晶完全溶解,然后分装到96孔培养板中,每个孔作3个平行孔,用酶标仪,以570nm波长测定光密度值。淋巴细胞的增殖能力用加ConA孔的光密度值减去不加ConA孔的光密度值表示。
1.2.2试验结果下表。
表2对ConA诱导的小鼠淋巴细胞转化试验的影响
由表2可见,本发明制剂1、2的中高剂量组连续对小鼠灌胃30天后,小鼠的淋巴细胞增殖能力与阴性对照组相比较均有显著性差异(P<0.05)。
1.3结论
由表1、表2的结果表明,本发明对小鼠的细胞免疫试验结果呈阳性。
2对小鼠NK细胞活性的影响
2.1试验方法:NK细胞活性测定(乳酸脱氢酶LDH测定法)
颈椎脱臼处死动物,取出脾脏,撕碎,过200目筛网后,用Hank’s液洗3 次,每次1000r/min离心10min,取细胞浆,灭菌水裂解红细胞,台酚兰染色计数(应在95%以上),用完全1640培养液配成2x107个/ml细胞悬液。将各只小鼠的细胞悬液取300μl分置于96孔培养板中,每孔100μl,每孔加靶细胞(YAC-1 细胞,4x105个/m)100μl,同时做靶细胞自然释放孔(靶细胞100μl,培养液100μl) 及最大释放孔(靶细胞100μ+2.5%Triton 100μl)各3孔,37℃5%CO2培养4小时,取出1500r/min离心5min。将各孔上清液100μl置于另一培养板中,每孔加入100μl基质,10分钟后加1mol/LHCL30μl终止反应,在490nm处测定OD 值,计算NK细胞活性率。
2.2试验结果,见表3。
表3对小鼠NK细胞活性的影响
由表3可见,本发明制剂1、2的中高剂量组连续对小鼠灌胃30天后,小鼠 NK细胞活性与阴性对照组相比,经统计学处理,均有显著性差异(P<0.05)。
2.3结论
表3的结果表明,本发明对小鼠NK细胞活性试验结果阳性。
综上,本发明对小鼠细胞免疫试验结果呈阳性、对小鼠NK细胞活性试验结果呈阳性。本发明具有增强免疫力的作用。
实施例9
抗抑郁作用试验
(一)受试药
本发明制剂1:按实施例2制备得胶囊剂,加水制成混悬液。
本发明制剂2:按实施例2制备得片剂,加水制成混悬液。
阴性对照:蒸馏水。
(二)试验动物:雄性ICR小鼠,体重20-24g,由四川省医学科学院实验动物研究所提供。
(三)试验数据采用SPSS 10.0for Windows软件包处理。
(四)试验方法及结果
1动物及分组
健康雄性昆明种小鼠,体质量20-24g,清洁级动物。动物经3天适应性喂养后,随机分组,自由摄食和饮水,并维持室温(22±2)℃,相对湿度(55±5)%,每笼5只。行为学实验于在安静温暖的环境中,各实验组平行进行。
2悬尾实验
取70只雄性小鼠,实验室适应3天后,进行悬尾实验筛选,剔除不动时间不足20s或超过160s的小鼠,选取50只,按不动时间长短随机分为阴性对照组,试验组,每组10只;每天上午按时给药,连续7天,每次给药前1h禁食不禁水。第3次和第7次给药后1h进行悬尾实验。动物为克服不正常***而挣扎活动,但活动一段时间后,出现间断性不动,显示失望状态。观察6min,记录后5min内的累计不动时间。
试验结果见表4。
表4小鼠悬尾实验结果表
由表4可见,本发明制剂1、2的中高剂量组减少小鼠悬尾实验中的不动时间与阴性对照组相比,经统计学处理,均有显著性差异(P<0.05)。
3强迫游泳实验
取70只雄性小鼠,实验室适应3天后,进行悬尾实验筛选,剔除不动时间不足20s或超过160s的小鼠,选取50只,按不动时间长短随机分为阴性对照组,试验组,每组10只;第3次和第7次给药后1h进行强迫游泳实验。将小鼠分别置于一透明玻璃容器中游泳6min,累计后4min内小鼠在水中停止挣扎或者呈漂浮状态,仅微小肢体运动以保持头部浮在水面的持续时间(即不动时间)。每只动物更换一次水。
试验结果,见表5。
表5强迫游泳实验结果表
由表5可见,本发明制剂1、2的低、中、高剂量组减少强迫游泳实验中的不动时间与阴性对照组相比,经统计学处理,均有显著性差异(P<0.05)。
综上,本发明能减少小鼠悬尾实验和强迫游泳实验中的不动时间。本发明具有抗抑郁的作用。
上述实施例仅为本发明的优选实施方式之一,不应当用于限制本发明的保护范围,但凡在本发明的主体设计思想和精神上作出的毫无实质意义的改动或润色,其所解决的技术问题仍然与本发明一致的,均应当包含在本发明的保护范围之内。
Claims (3)
1.一种增强人体免疫力和抗抑郁保健食品的制备方法,其特征在于,包括如下步骤:
步骤1、按重量份数准备原料,所述原料及其重量配比为:灵芝2~10份、刺五加6~18份、三七4~12份、栀子1~6份;
步骤2、将刺五加、栀子加水煎煮,煎液滤过,合并滤液,滤液减压浓缩得到清膏,备用;
步骤3、将灵芝、三七粉碎,过筛,得细粉,备用;
步骤4、将步骤2所得清膏干燥得干浸膏;
步骤5、将步骤4所得干浸膏粉碎过筛,得干浸膏粉;
步骤6、将步骤3所得细粉与步骤5所得干浸膏粉混合均匀,加入适量85%乙醇为湿润剂制软材;
步骤7、将步骤6所得软材过筛制粒,得湿颗粒,湿颗粒干燥,整粒,装胶囊,包装,即得胶囊剂。
2.根据权利要求1所述的一种增强人体免疫力和抗抑郁保健食品的制备方法,其特征在于,所述步骤1中,所述原料及其重量配比为:灵芝3~8份、刺五加7~15份、三七5~10份、栀子2~5份。
3.根据权利要求2所述的一种增强人体免疫力和抗抑郁保健食品的制备方法,其特征在于,所述步骤1中,所述原料及其重量配比为:灵芝4份、刺五加12份、三七6份、栀子2份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710306375.4A CN107252110A (zh) | 2017-05-04 | 2017-05-04 | 一种增强人体免疫力和抗抑郁保健食品的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710306375.4A CN107252110A (zh) | 2017-05-04 | 2017-05-04 | 一种增强人体免疫力和抗抑郁保健食品的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107252110A true CN107252110A (zh) | 2017-10-17 |
Family
ID=60027563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710306375.4A Pending CN107252110A (zh) | 2017-05-04 | 2017-05-04 | 一种增强人体免疫力和抗抑郁保健食品的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107252110A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569642A (zh) * | 2008-04-30 | 2009-11-04 | 北京卓越同创药物研究院 | 一种促进睡眠的药物组合物及其制备和应用 |
CN106214844A (zh) * | 2016-08-26 | 2016-12-14 | 成都润馨堂药业有限公司 | 一种具有减肥和免疫调节作用的组合物及其制备方法 |
-
2017
- 2017-05-04 CN CN201710306375.4A patent/CN107252110A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569642A (zh) * | 2008-04-30 | 2009-11-04 | 北京卓越同创药物研究院 | 一种促进睡眠的药物组合物及其制备和应用 |
CN106214844A (zh) * | 2016-08-26 | 2016-12-14 | 成都润馨堂药业有限公司 | 一种具有减肥和免疫调节作用的组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
黄世敬主编: "《抗抑郁中药良方》", 28 February 2016, 金盾出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103893549B (zh) | 一种缓解疲劳的中药组合物及其制备方法和用途 | |
CN102204678B (zh) | 一种具有增强免疫力功效的即食燕窝粉及其制备方法 | |
CN106072578A (zh) | 具有增强人体免疫功能的酵素组合物、泡腾片及制法 | |
CN105341893A (zh) | 一种辅助降血糖的组合物及应用 | |
CN106579419A (zh) | 一种缓解疲劳、恢复体力、补充能量的功能食品组合物 | |
CN104489172A (zh) | 一种提高免疫力的刺五加保健茶及其制备方法 | |
CN108066384A (zh) | 一种具有增强免疫力功能的中药制剂及其制备方法 | |
CN104225295B (zh) | 用于改善睡眠的组合物及其制备方法和应用 | |
CN106490558A (zh) | 一种保健蜂蜜及其制备方法 | |
CN103623138B (zh) | 一种中药组合物在制备治疗糖尿病氧化应激药物中的应用 | |
CN105687479B (zh) | 一种枣杞花中药组合物 | |
CN108498769A (zh) | 一种药酒及其制备方法与应用 | |
CN107737280A (zh) | 用于治疗糖尿病的中药组合物及其制备方法和应用 | |
CN107252110A (zh) | 一种增强人体免疫力和抗抑郁保健食品的制备方法 | |
CN104666888A (zh) | 一种提高免疫力的中药保健品 | |
CN104435072B (zh) | 一种具有辅助降血糖、降血脂的提取物及其制备方法 | |
CN107252086A (zh) | 一种增强人体免疫力和抗抑郁的保健食品 | |
CN114432384A (zh) | 一种低氘水龙脑雾化护眼液 | |
CN107115478A (zh) | 一种治疗失眠的中药组合物、其制备方法和应用 | |
CN115089661A (zh) | 辅助调节内分泌代谢并抗癌防癌的人参组合物的应用 | |
CN107115515A (zh) | 一种降血糖保健中药组合物及其制备方法 | |
CN105920053A (zh) | 桑黄精细粉制备方法 | |
CN106107654A (zh) | 一种高原梨果含片 | |
CN111557447A (zh) | 一种铁皮石斛多糖含片的制备及其在免疫增强作用上的应用 | |
CN105748823A (zh) | 一种美容养颜中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171017 |